Phase I/II Study of Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Phase of Trial: Phase I/II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Neuroblastoma
- Focus Adverse reactions
- 17 May 2016 Study phase changed from I to I/II (addition of an expansion phase); Treatment for phase II (expansion phase) added and patient number changed.
- 17 May 2016 Planned number of patients changed from 102 to 224.
- 17 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2021.